Caplin Point Laboratories Ltd Stock Price Today (NSE: CAPLIPOINT)
Fundamental Score
Caplin Point Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Caplin Point Laboratories Ltd share price today is ₹1722.30, up +0.00% on NSE/BSE as of 17 February 2026. Caplin Point Laboratories Ltd (CAPLIPOINT) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹14.50K (Cr). The 52-week high for CAPLIPOINT share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 24.62x, CAPLIPOINT is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 22.66% and a debt-to-equity ratio of 0.00.
Caplin Point Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Caplin Point Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Caplin Point Laboratories Share Price: A Financial Analysis
A key dynamic in the pharmaceutical industry is the increasing focus on niche therapeutic areas and emerging markets. Companies that strategically target these areas often experience higher growth rates. This analysis explores the financial standing of Caplin Point Laboratories Ltd, currently trading at ₹1825.699951, focusing on its key metrics and competitive positioning. The performance of Caplin Point Laboratories share price reflects investor sentiment, which is closely tied to the company's profitability and growth potential.
With a PE ratio of 24.62, Caplin Point Laboratories Ltd appears reasonably valued when compared to the broader market, but a closer look at its peers is crucial. Compared to
Mankind Pharma Ltd, whose management has consistently demonstrated strong capital allocation skills and execution, Caplin Point Laboratories Ltd needs to show that it can consistently meet guidance and show similar skills for investor confidence to grow. While both operate in the pharmaceutical sector, their approaches to market penetration and portfolio diversification might differ, warranting further investigation.A standout metric for Caplin Point Laboratories Ltd is its Return on Capital Employed (ROCE) of 25.85%. This high ROCE signifies efficient capital utilization and contributes significantly to building the company's economic moat. A higher ROCE compared to its cost of capital implies that Caplin Point Laboratories Ltd is generating substantial returns on its investments, creating a competitive advantage. This enables the company to reinvest profits, potentially driving further growth and solidifying its market position against competitors like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd.
In conclusion, while the current Caplin Point Laboratories share price reflects one view of its value, understanding its ROCE and management's ability to execute is key to understanding future performance. This observational financial analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. It is intended for informational purposes only and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Caplin Point Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CAPLIPOINT across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (22.66%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.85%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (31.89%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 24.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (17.55% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (20.36% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.48% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (1072.58x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹932.15 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.57%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 8.61%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Caplin Point Laboratories Ltd Financial Statements
Comprehensive financial data for Caplin Point Laboratories Ltd including income statement, balance sheet and cash flow
About CAPLIPOINT (Caplin Point Laboratories Ltd)
Caplin Point Laboratories Ltd (CAPLIPOINT) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹14.50K (Cr). Caplin Point Laboratories Ltd has delivered a Return on Equity (ROE) of 22.66% and a ROCE of 25.85%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking CAPLIPOINT share price can monitor key metrics including P/E ratio, promoter holding of 70.57%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
CAPLIPOINT Share Price: Frequently Asked Questions
What is the current share price of Caplin Point Laboratories Ltd (CAPLIPOINT)?
As of 17 Feb 2026, 10:08 am IST, Caplin Point Laboratories Ltd share price is ₹1722.30. The CAPLIPOINT stock has a market capitalisation of ₹14.50K (Cr) on NSE/BSE.
Is CAPLIPOINT share price Overvalued or Undervalued?
CAPLIPOINT share price is currently trading at a P/E ratio of 24.62x, compared to the industry average of 31.77x. Based on this relative valuation, the Caplin Point Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CAPLIPOINT share price?
The 52-week high of CAPLIPOINT share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Caplin Point Laboratories Ltd share price?
Key factors influencing CAPLIPOINT share price include quarterly earnings growth (Sales Growth: 10.54%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Caplin Point Laboratories Ltd a good stock for long-term investment?
Caplin Point Laboratories Ltd shows a 5-year Profit Growth of 20.48% and an ROE of 22.66%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in CAPLIPOINT shares.
How does Caplin Point Laboratories Ltd compare with its industry peers?
Caplin Point Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare CAPLIPOINT share price P/E of 24.62x and ROE of 22.66% against the industry averages to determine competitive standing.
What is the P/E ratio of CAPLIPOINT and what does it mean?
CAPLIPOINT share price has a P/E ratio of 24.62x compared to the industry average of 31.77x. Investors pay ₹25 for every ₹1 of annual earnings.
How is CAPLIPOINT performing according to Bull Run's analysis?
CAPLIPOINT has a Bull Run fundamental score of 64/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CAPLIPOINT belong to?
CAPLIPOINT operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Caplin Point Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for CAPLIPOINT?
CAPLIPOINT has an ROE of 22.66%, which indicates excellent management efficiency. ROE measures how efficiently Caplin Point Laboratories Ltd generates profits from shareholders capital.
How is CAPLIPOINT debt-to-equity ratio and what does it indicate?
CAPLIPOINT has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is CAPLIPOINT dividend yield and is it a good dividend stock?
CAPLIPOINT offers a dividend yield of 0.31%, meaning you receive ₹0.31 annual dividend for every ₹100 invested in Caplin Point Laboratories Ltd shares.
How has CAPLIPOINT share price grown over the past 5 years?
CAPLIPOINT has achieved 5-year growth rates of: Sales Growth 17.55%, Profit Growth 20.48%, and EPS Growth 20.36%.
What is the promoter holding in CAPLIPOINT and why does it matter?
Promoters hold 70.57% of CAPLIPOINT shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Caplin Point Laboratories Ltd.
What is CAPLIPOINT market capitalisation category?
CAPLIPOINT has a market capitalisation of ₹14497 crores, placing it in the Mid-cap category.
How volatile is CAPLIPOINT stock?
CAPLIPOINT has a beta of N/A. A beta > 1 suggests the Caplin Point Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CAPLIPOINT operating profit margin trend?
CAPLIPOINT has a 5-year average Operating Profit Margin (OPM) of 31.89%, indicating the company's operational efficiency.
How is CAPLIPOINT quarterly performance?
Recent quarterly performance shows Caplin Point Laboratories Ltd YoY Sales Growth of 10.54% and YoY Profit Growth of 18.08%.
What is the institutional holding pattern in CAPLIPOINT?
CAPLIPOINT has FII holding of 6.51% and DII holding of 2.10%. Significant institutional holding often suggests professional confidence in the Caplin Point Laboratories Ltd stock.